Media headlines about Jaguar Health (NASDAQ:JAGX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Jaguar Health earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.9586940092008 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Separately, ValuEngine raised shares of Jaguar Health from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.
Shares of NASDAQ JAGX traded up $0.01 on Thursday, reaching $1.78. 200 shares of the company traded hands, compared to its average volume of 391,535. Jaguar Health has a fifty-two week low of $1.56 and a fifty-two week high of $14.85. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.52.
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.